NCT06425276View on ClinicalTrials.gov

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

July 8, 2021

Study Completion Date

September 18, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Melphalan Hydrochloride for Injection

During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

CASI Pharmaceuticals (China) Co., Ltd.

INDUSTRY

NCT06425276 - Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | Biotech Hunter | Biotech Hunter